A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

February 27, 2025

Study Completion Date

February 27, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

BMS-986416

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

Trial Locations (19)

2650

Local Institution - 0043, Edegem

9000

Local Institution - 0016, Ghent

15232

Local Institution - 0003, Pittsburgh

21287

Local Institution - 0005, Baltimore

30322

Local Institution - 0006, Atlanta

77030

Local Institution - 0004, Houston

7500921

Local Institution - 0025, Santiago

7620002

Local Institution - 0026, Santiago

8420383

Local Institution - 0024, Santiago

07601

Local Institution - 0002, Hackensack

44106-1716

Local Institution - 0013, Cleveland

C1426ANZ

Local Institution - 0021, Ciudad Autónoma de Buenos Aires

C1199ABB

Local Institution - 0027, ABB

C1430EGF

Local Institution - 0022, CABA

T6X 1E8

Local Institution - 0009, Edmonton

M5G 2M9

Local Institution - 0008, Toronto

H2X 3H8

Local Institution - 0001, Montreal

104-0045

Local Institution - 0010, Chuo-ku

6229 HX

Local Institution - 0020, Maastricht

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04943900 - A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | Biotech Hunter | Biotech Hunter